Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Augmentin 375mg tablets
0501013K0BBAAAA
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 280 |
|
Zithromax 250mg capsules
0501050A0BBAAAA
|
Zithromax | Azithromycin | Infections | 274 |
|
Cefixime 200mg tablets
0501021C0AAAAAA
|
Cefixime | Cefixime | Infections | 270 |
|
Rifadin 150mg capsules
0501090R0BBAAAA
|
Rifadin | Rifampicin | Infections | 263 |
|
Fluconazole 200mg/5ml oral suspension
0502010B0AAAHAH
|
Fluconazole | Fluconazole | Infections | 262 |
|
Rifampicin 100mg/5ml oral suspension
0501090R0AAAFAF
|
Rifampicin | Rifampicin | Infections | 253 |
|
Famciclovir 125mg tablets
0503021E0AAABAB
|
Famciclovir | Famciclovir | Infections | 237 |
|
Valaciclovir 1g tablets
0503021A0AAAHAH
|
Valaciclovir | Valaciclovir | Infections | 237 |
|
Chloroquine phosphate 250mg tablets
0504010F0AAABAB
|
Chloroquine phosphate | Chloroquine phosphate | Infections | 230 |
|
Atovaquone 750mg/5ml oral suspension sugar free
0504080A0AAABAB
|
Atovaquone | Atovaquone | Infections | 209 |
|
Erythrocin 250 tablets
0501050N0BBAAAA
|
Erythrocin (Systemic) | Erythromycin stearate | Infections | 204 |
|
Ceftriaxone 1g powder for solution for injection vials
0501021G0AAACAC
|
Ceftriaxone sodium | Ceftriaxone sodium | Infections | 194 |
|
Cefaclor 250mg/5ml oral suspension
0501021A0AAACAC
|
Cefaclor | Cefaclor | Infections | 187 |
|
Tamiflu 30mg capsules
0503040B0BBACAC
|
Tamiflu | Oseltamivir phosphate | Infections | 186 |
|
Cefadroxil 500mg capsules
0501021B0AAAAAA
|
Cefadroxil | Cefadroxil | Infections | 164 |
|
Griseofulvin 125mg/5ml oral suspension
0502050B0AACUCU
|
Griseofulvin (Systemic) | Griseofulvin | Infections | 163 |
|
Co-fluampicil 250mg/250mg capsules
0501013L0AAAAAA
|
Co-fluampicil | Co-fluampicil(Flucloxacillin/ampicillin) | Infections | 158 |
|
Minocycline 100mg capsules
0501030P0AAAEAE
|
Minocycline hydrochloride (Systemic) | Minocycline hydrochloride | Infections | 150 |
|
Gentamicin 80mg/2ml solution for injection vials
0501040H0AAAMAM
|
Gentamicin sulfate (Systemic) | Gentamicin sulfate | Infections | 147 |
|
Nystatin 100,000units/ml oral suspension sugar free
0502030B0AAAXAX
|
Nystatin (Systemic) | Nystatin | Infections | 146 |
|
Rifinah 300mg/150mg tablets
0501090S0BBABAB
|
Rifinah | Rifampicin combined preparations | Infections | 145 |
|
Diflucan 150mg capsules
0502010B0BBABAB
|
Diflucan | Fluconazole | Infections | 139 |
|
Erythromycin 250mg gastro-resistant capsules
0501050C0AAAKAK
|
Erythromycin (Systemic) | Erythromycin | Infections | 137 |
|
Erythrocin 500 tablets
0501050N0BBABAB
|
Erythrocin (Systemic) | Erythromycin stearate | Infections | 125 |
|
Ciprofloxacin 100mg tablets
0501120L0AAAGAG
|
Ciprofloxacin (Systemic) | Ciprofloxacin | Infections | 123 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.